CD70 and PD‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy
- 16 June 2017
- journal article
- Published by Wiley in Histopathology
- Vol. 71 (3) , 357-365
Abstract
Aims: During recent years, immune checkpoint inhibition has proved to be effective in several solid malignancies. The aim of this study was to identify novel targets for immunotherapy in anaplastic thyroid cancer by analysis of the expression of tumour antigens for which therapeutic agents are available.Method and results: By immunohistochemistry we observed tumoral expression of CD70 in 49% of cases. Expression of its receptor, CD27, was present mainly in lymphocytes surrounding and infiltrating the tumour and observed only rarely in tumour cells. CD70 expression was associated with the presence of a precursor papillary thyroid carcinoma and the presence of BRAF V600E mutations in the anaplastic thyroid cancer lesion. Furthermore, the expression of CD70 seems stable during progression of the disease. Tumoral expression of programmed cell death ligand 1 (PD‐L1) was found in 28.6% of the anaplastic thyroid cancer cases. Programmed cell death 1 (PD‐1), the receptor of PD‐L1, was not expressed on the tumour cells. No association between CD70 expression and PD‐L1 expression could be demonstrated.Conclusion: These data suggest that targeted immunotherapy for CD70/CD27 and PD‐L1/PD‐1 might be promising in anaplastic thyroid cancer. However, as a low amount of tumour‐infiltrating lymphocytes was observed in most lesions, combined therapy with agents enhancing the invasion of lymphocytes in the tumour region needs to be considered.Keywords
This publication has 32 references indexed in Scilit:
- The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancerOncoTargets and Therapy, 2013
- Modulating CD27 signaling to treat cancerOncoImmunology, 2012
- Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCRPLOS ONE, 2011
- Timing and tuning of CD27–CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathologyImmunological Reviews, 2009
- Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70Clinical Cancer Research, 2008
- CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25− T cellsBlood, 2007
- Elimination of chronic viral infection by blocking CD27 signalingJournal of Experimental Medicine, 2006
- Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug ConjugatesCancer Research, 2006
- Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomasMolecular Cancer Therapeutics, 2005
- CD27 and CD70 in T cell and B cell activationCurrent Opinion in Immunology, 2005